Galectin Therapeutics
GALT
GALT
76 hedge funds and large institutions have $35.4M invested in Galectin Therapeutics in 2019 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
5% less capital invested
Capital invested by funds: $37.3M → $35.4M (-$1.94M)
39% less call options, than puts
Call options by funds: $894K | Put options by funds: $1.46M
Holders
76
Holding in Top 10
–
Calls
$894K
Puts
$1.46M
Top Buyers
| 1 | +$6.02M | |
| 2 | +$1.73M | |
| 3 | +$785K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$519K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$476K |
Top Sellers
| 1 | -$1.47M | |
| 2 | -$891K | |
| 3 | -$877K | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$759K |
| 5 |
JPMorgan Chase & Co
New York
|
-$722K |